Mass General Brigham researchers found that the intensive cholesterol-lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high-risk patients who did not have known ...

For the first time since 2018, a clinical guideline from the American College of Cardiology and the American Heart Association for screening and managing blood cholesterol levels has been updated and ...

The cholesterol-lowering therapy evolocumab reduced the risk of major adverse cardiac events by nearly one-third among patients who had no known significant atherosclerosis and had diabetes, according ...